Literature DB >> 11054089

Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa.

A Szczeklik1, A Undas, M Sanak, M Frolow, W Wegrzyn.   

Abstract

A single nucleotide T to C transition of the gene encoding glycoprotein IIIa leads to a common diallelic polymorphism Leu-33-->Pro (PLA1/A2). We studied the relationship between the PlA1/A2 polymorphism and platelet function in 80 healthy men, aged 20-25 years. Before aspirin ingestion, bleeding time (BT) was shorter in carriers of the PlA2 than in carriers of the PlA1/A1 allele. At 4 h after ingestion of 300 mg of aspirin, BT became prolonged, and the intergroup difference was enhanced. In seven out of 26 PLA2 allele carriers, aspirin shortened BT on average by 30 s, compared with only one among 54 subjects with the PlA1/A1 genotype. Thus, BT both at baseline and after aspirin depends on the PlA1/A2 polymorphism of glycoprotein IIIa. Carriers of the PlA2 allele appear to be more resistant to the antithrombotic action of aspirin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11054089     DOI: 10.1046/j.1365-2141.2000.02267.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

Review 1.  Role of platelet glycoprotein polymorphisms in cardiovascular diseases.

Authors:  Christian Meisel; José A López; Karl Stangl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-12       Impact factor: 3.000

2.  Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Lutz Edler; Jan Lubinski; Rodney J Scott; Ute Hamann
Journal:  J Med Genet       Date:  2007-01-12       Impact factor: 6.318

3.  Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.

Authors:  James R Cerhan; Stephen M Ansell; Zachary S Fredericksen; Neil E Kay; Mark Liebow; Timothy G Call; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Wen Liu-Mares; William R Macon; Diane Jelinek; Thomas E Witzig; Thomas M Habermann; Susan L Slager
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

Review 4.  The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis.

Authors:  Christopher N Floyd; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

Review 5.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Authors:  Anetta Undas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

6.  Aspirin resistance: Fact or fiction? A point of view.

Authors:  Jawahar L Mehta; Bhavna Mohandas
Journal:  World J Cardiol       Date:  2010-09-26

7.  Pharmacogenetics of cardiovascular drug therapy.

Authors:  Bas J M Peters; Olaf H Klungel; Anthonius de Boer; Bruno H Ch Stricker; Anke-Hilse Maitland-van der Zee
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 8.  Pharmacogenetics of aspirin resistance: a comprehensive systematic review.

Authors:  Timothy Goodman; Albert Ferro; Pankaj Sharma
Journal:  Br J Clin Pharmacol       Date:  2008-04-22       Impact factor: 4.335

9.  The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.

Authors:  Anna Jakubowska; Dominik Rozkrut; Antonis Antoniou; Ute Hamann; Jan Lubinski
Journal:  Breast Cancer Res Treat       Date:  2009-10-30       Impact factor: 4.872

10.  Aspirin resistance.

Authors:  Khaled Mansour; Ali T Taher; Khaled M Musallam; Samir Alam
Journal:  Adv Hematol       Date:  2009-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.